Michael J. Gitlin, MD.
Professor of Clinical Psychiatry and Director of the Mood Disorders Clinic at the David Geffen School of Medicine at UCLA; coauthor of The Essential Guide to Lithium Treatment (Springer, 2016).
Dr. Gitlin has no financial relationships with companies related to this material.
Michael J. Gitlin, M.D.
Professor of Clinical Psychiatry, UCLA School of Medicine
Director of the Mood Disorders Clinic, UCLA Neuropsychiatric Hospital
Dr. Gitlin has disclosed that he is a member of the speakers bureau of Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Astra Zeneca, and Janssen. Dr. Gitlin has disclosed that psychostimulants, modafinil, and T3 have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression.
Please consult product labeling for the approved usages._-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
